Evidence map›Paper›PMID 27437764›Full record

ArticleOncotarget2016

[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.

Il Minn, Soo Min Koo, Hye Soo Lee, Mary Brummet, Steven P Rowe, Michael A Gorin, Polina Sysa-Shah, William D Lewis, Hye-Hyun Ahn, Yuchuan Wang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Molecular Imaging Diagnosis of Renal Cancer UsingDiagnostics (Basel, Switzerland) · 2023
    Review
  11. Promise of hypoxia-targeted tracers in metastatic lymph node imaging.European journal of nuclear medicine and molecular imaging · 2022
    Article
  12. Review
  13. Review
  14. Non-invasive molecular imaging of kidney diseases.Nature reviews. Nephrology · 2021
    Review
  15. Article
  16. Review
  17. International journal of molecular sciences · 2020
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Il MinnRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Soo Min KooRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hye Soo LeeRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mary BrummetRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Steven P RoweRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael A GorinThe James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Polina Sysa-ShahRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
William D LewisRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hye-Hyun AhnRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yuchuan WangRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sangeeta Ray BanerjeeRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ronnie C MeaseRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sridhar NimmagaddaRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mohamad E AllafThe James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Martin G PomperRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Xing YangRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

PSMA-based Cancer Imaging AgentsR01CA134675 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI POMPER, MARTIN G · 2009 to 2025
$6.2M
Small Molecule PSMA-Targeted Alpha TherapyR01CA184228 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI POMPER, MARTIN G, ZALUTSKY, MICHAEL ROD · 2014 to 2023
$3.6M
PSMA Directed Imaging of Prostate Cancer Focus on Androgen Receptor DynamicsU01CA183031 · NCI · JOHNS HOPKINS UNIVERSITY · PI DEWEESE, THEODORE L, POMPER, MARTIN G · 2015 to 2017
$1.2M
Specific Molecular Imaging Agents for Clear Cell Renal Cell Carcinoma DiagnosisR03CA197470 · NCI · JOHNS HOPKINS UNIVERSITY · PI YANG, XING · 2015 to 2016
$162k
NCI NIH HHS R01 CA134675NCI NIH HHS R01 CA184228NCI NIH HHS R03 CA197470NCI NIH HHS U01 CA183031
6 · The paper itself

Abstract

Carbonic anhydrase IX (CAIX) is a cell surface enzyme that is over-expressed in approximately 95% of cases of clear cell renal cell carcinoma (ccRCC), the most common renal cancer. We synthesized and performed in vitro and in vivo evaluation of a dual-motif ligand, [64Cu]XYIMSR-06, for imaging CAIX expression on ccRCC tumors using positron emission tomography (PET). [64Cu]XYIMSR-06 was generated in yields of 51.0 ± 4.5% (n=5) and specific activities of 4.1 - 8.9 GBq/μmol (110-240 Ci/mmol). Tumor was visualized on PET images by 1 h post-injection with high tumor-to-background levels (>100 tumor-to-blood and -muscle) achieved within 24 h. Biodistribution studies demonstrated a maximum tumor uptake of 19.3% injected dose per gram of radioactivity at 4 h. Tumor-to-blood, -muscle and -kidney ratios were 129.6 ± 18.8, 84.3 ± 21.0 and 2.1 ± 0.3, respectively, at 8 h post-injection. At 24 h a tumor-to-kidney ratio of 7.1 ± 2.5 was achieved. These results indicate pharmacokinetics superior to those of previously reported imaging agents binding to CAIX. [64Cu]XYIMSR-06 is a new low-molecular-weight PET ligand targeting CAIX, which can image localized and metastatic ccRCC.

Indexed as

Positron-Emission TomographyAnimalsAntigens, NeoplasmCarbonic Anhydrase IXCarcinoma, Renal CellCell Line, TumorCopper RadioisotopesFemaleGene Expression Regulation, NeoplasticHumansKidney NeoplasmsLigandsMiceMice, Inbred NODMice, SCIDNeoplasm MetastasisAntigens, NeoplasmCA9 protein, humanCarbonic Anhydrase IXCopper RadioisotopesLigandsRadiopharmaceuticalscarbonic anhydrase IXcopper-64molecular imagingpositron emission tomographyrenal cell carcinoma

Identifiers

PMID27437764
PMCPMC5302928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.